Allergies News and Research

Latest Allergies News and Research

NIAID, Aeras partner for Phase II clinical trial of TB vaccine

Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

1 Feb 2012

Milestone for Starpharma's drug delivery program

Starpharma Holdings today released animal data which demonstrated that its dendrimer-docetaxel formulation applying Starpharma’s dendrimer technology to the leading chemotherapy drug docetaxel was significantly more efficacious than docetaxel (Taxotere®) in a breast cancer model.

1 Feb 2012

Gottlieb to open new health center in the near west suburbs

Gottlieb Memorial Hospital is opening a new health center designed around the needs of patients in the near west suburbs. The Gottlieb Center for Immediate Care at River Forest, 7617 W. North Ave., is part of the Loyola University Health System. Physicians from both the Loyola Maywood and the Gottlieb Melrose Park campuses will together care for patients at the nearly 10,000 square-foot new facility.

31 Jan 2012

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012.

31 Jan 2012

NAET safe and effective in treating children with allergy-related autism

Researchers at the NAET Autism Treatment Center in Buena Park, CA, hypothesized that major contributors to the development and symptoms of autism include food and nutrient sensitivities. They applied NAET, a combination of a special form of acupressure and kinesiology, to desensitize subjects to multiple allergens as a way to treat symptoms of autism.

31 Jan 2012

Genetic technology to make inedible seeds more edible

Every night millions of people go to bed hungry. New genetic technology can help us feed the world by making inedible seeds more edible.

30 Jan 2012

Heartburn drugs ineffective in kids with asthma: Study

A drug used to treat acid reflux has often been used for hard-to-treat asthma. A new study finds that it does not help children with the breathing disease and may cause side effects.

24 Jan 2012

Scientists halt bird flu research for 60 days amid safety concerns

The head of the NIH National Institute of Allergy and Infectious Diseases (NIAID), which funded "two projects that created a highly pathogenic [H5N1] flu virus mutation, has welcomed a two-month moratorium on further research while defending the value and safety of the experiments," the Financial Times reports.

24 Jan 2012

Novo Nordisk Type 1 Diabetes R&D Center to be established in Seattle

Novo Nordisk announced today that the company will establish a type 1 diabetes research and development center in Seattle, Wash., U.S. The new center will combine Novo Nordisk's history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy.

24 Jan 2012

Phenomenex, AB SCIEX collaborate to improve food testing

AB SCIEX, a global leader in life science analytical technologies, and Phenomenex, a global leader in separation science techniques, today announced a collaboration agreement designed to significantly improve food testing.

24 Jan 2012

NHS Choices launches new food allergy and intolerance myth buster tool

To mark food allergy and intolerance awareness week, NHS Choices, the health information website for the NHS, has launched a new tool to help dispel common myths around food allergy and intolerance.

21 Jan 2012

SERI researchers receive NEI grant to understand origins of eye allergies

The National Eye Institute has awarded researchers at the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear, a five year-grant totaling more than $2.4 million to understand the origins of eye allergies.

18 Jan 2012

Stallergenes chooses Magic Software's iBOLT integration platform

Magic Software Enterprises Ltd., a global provider of mobile and cloud-enabled application and business integration platforms, announced today that Stallergenes, a biopharmaceutical company and world leader in the treatment of severe allergic respiratory illnesses, has chosen Magic Software's iBOLT integration platform to integrate its various purchasing systems with its SAP ERP.

17 Jan 2012

Scientists discover specific immune system T cells that trigger destruction of type 1 diabetes

Researchers at the La Jolla Institute for Allergy & Immunology have proven - for the first time in human tissues -- the specific immune system T cells which trigger the destruction of type 1 diabetes in the pancreas. The finding is an important advance that verifies in humans several important disease characteristics shown in mouse studies and provides a key focal point for interrupting the disease process.

13 Jan 2012

Study examines impact of maternal obesity on inflammatory responses

A number of different immunological mechanisms ensure the successful establishment and maintenance of pregnancy. Imbalance in these mechanisms is associated with adverse pregnancy outcomes.

11 Jan 2012

ADHD diet: Review of studies

A new review finds that some foods may not be good for children with attention deficit-hyperactivity disorder (ADHD). Fast foods, red meat, processed foods, soft drinks, high fat dairy foods and potato chips may not be right.

10 Jan 2012

Novartis recalls four OTC drugs citing factory malfunction

Swiss pharmaceutical firm Novartis has announced that it is recalling four different products sold over the counter in the United States after receiving reports that there if malfunction at one of its plants.

9 Jan 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

NCH voluntarily recalls certain over-the-counter drugs in the U.S.

Novartis Consumer Health, Inc. (NCH) announced today that it is voluntarily recalling all lots of select bottle packaging configurations of Excedrin and NoDoz products with expiry dates of December 20, 2014 or earlier as well as Bufferin and Gas-X Prevention products with expiry dates of December 20, 2013 or earlier, in the United States.

8 Jan 2012

Anthrax defenses need to be strengthened say experts

It has been a decade since the anthrax attacks brought home the reality of bioterrorism and the nation has a stockpile of some basic tools to fight back against a few of the threats that worry defense experts the most.

8 Jan 2012